Details for Patent: 10,292,937
✉ Email this page to a colleague
Which drugs does patent 10,292,937 protect, and when does it expire?
Patent 10,292,937 protects JORNAY PM and is included in one NDA.
This patent has forty patent family members in fourteen countries.
Summary for Patent: 10,292,937
| Title: | Methods of treatment of attention deficit hyperactivity disorder |
| Abstract: | Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 7 hours or longer, followed by an ascending release rate. When administered at night the composition provides early morning improvement in symptoms of ADHD and sustained improvement over a period of at least 12 hours. |
| Inventor(s): | Lickrish; David (Grand Cayman, KY), Zhang; Feng (Pflugerville, TX) |
| Assignee: | IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC. (Camana Bay, KY) |
| Application Number: | 15/470,697 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Dosage form; |
Drugs Protected by US Patent 10,292,937
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironshore Pharms | JORNAY PM | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 209311-001 | Aug 8, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Sign Up | ||||
| Ironshore Pharms | JORNAY PM | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 209311-002 | Aug 8, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Sign Up | ||||
| Ironshore Pharms | JORNAY PM | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 209311-003 | Aug 8, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Sign Up | ||||
| Ironshore Pharms | JORNAY PM | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 209311-004 | Aug 8, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Sign Up | ||||
| Ironshore Pharms | JORNAY PM | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 209311-005 | Aug 8, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,292,937
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2012230733 | ⤷ Sign Up | |||
| Australia | 2016228307 | ⤷ Sign Up | |||
| Australia | 2018202002 | ⤷ Sign Up | |||
| Brazil | 112013024401 | ⤷ Sign Up | |||
| Canada | 2830788 | ⤷ Sign Up | |||
| China | 103608004 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
